Stay updated on Soticlestat in Rare Epilepsies Clinical Trial
Sign up to get notified when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.
Latest updates to the Soticlestat in Rare Epilepsies Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s footer revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a minor site release without changing the clinical trial information presented.SummaryDifference0.0%
- Check28 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%
- Check42 days agoChange DetectedThe ENDYMION 1 study (NCT03635073) was terminated due to negative results from related phase 3 studies, and supplementary data were deemed unnecessary. The record now reflects the termination and includes posted results and QC date updates in 2026.SummaryDifference0.1%
- Check50 days agoChange DetectedAdded 'Severe myoclonic epilepsy in infancy' to the Conditions section and removed 'Dravet syndrome'.SummaryDifference0.0%
- Check57 days agoChange DetectedAdded a Results Posted entry with detailed long-term safety and outcome data (ECG, vital signs, labs, seizures, and behavioral measures) and related documentation; removed the prior Results Submitted content and associated metrics.SummaryDifference4%
- Check71 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%
Stay in the know with updates to Soticlestat in Rare Epilepsies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.